Ioversol
As of the edition of 20 October 2026, Ioversol is a small molecule: marketed, first approved in 1988 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Optiray 240
- First approved
- 30 December 1988 (US)
- Approvals on record
- 18 in 5 regions
- Holder of the most recent approval
- GUERBET IMAGEM DO BRASIL LTDA; 4 holders in all
- Registered trials
- 4, 2 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Blood and lymph; Cancer; Digestive system; Immune system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 0 | 0 | 2 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Liebel-Flarsheim | Acquired holder | 2015 to now |
| Byk-Mallinckrodt CIL | Originator | 1988 to 2015 |